Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    StockNews24StockNews24
    Subscribe
    • Shares
    • News
      • Featured Company
      • News Overview
        • Company news
        • Expert Columns
        • Germany
        • USA
        • Price movements
        • Default values
        • Small caps
        • Business
      • News Search
        • Stock News
        • CFD News
        • Foreign exchange news
        • ETF News
        • Money, Career & Lifestyle News
      • Index News
        • DAX News
        • MDAX News
        • TecDAX News
        • Dow Jones News
        • Eurostoxx News
        • NASDAQ News
        • ATX News
        • S&P 500 News
      • Other Topics
        • Private Finance News
        • Commodity News
        • Certificate News
        • Interest rate news
        • SMI News
        • Nikkei 225 News1
    • Carbon Markets
    • Raw materials
    • Funds
    • Bonds
    • Currency
    • Crypto
    • English
      • العربية
      • 简体中文
      • Nederlands
      • English
      • Français
      • Deutsch
      • Italiano
      • Português
      • Русский
      • Español
    StockNews24StockNews24
    Home » Twist Bioscience director Robert Chess sells $250,000 in stock By Investing.com
    News

    Twist Bioscience director Robert Chess sells $250,000 in stock By Investing.com

    userBy userJanuary 10, 2025No Comments2 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email



    Robert Chess, a director at Twist Bioscience Corp (NASDAQ:TWST), recently sold 5,000 shares of the company’s common stock, according to a recent filing with the Securities and Exchange Commission. The shares were sold at a price of $50.00 each, amounting to a total transaction value of $250,000. The transaction price represents a premium to the current trading price of $43.60, with the stock showing notable volatility according to InvestingPro data. Following this sale, Chess holds 16,641 shares directly. Additionally, the Chess 1997 Trust, for which Chess and his spouse are the sole trustees and beneficiaries, owns 42,528 shares indirectly. The transactions were executed under a Rule 10b5-1 trading plan that Chess adopted in August 2024. Twist Bioscience, currently valued at $2.6 billion, maintains strong liquidity with a current ratio of 4.88. InvestingPro analysis reveals 6 additional key insights about TWST’s financial health and growth prospects, available in the comprehensive Pro Research Report covering 1,400+ top stocks.

    In other recent news, Twist Bioscience Corporation (NASDAQ:) concluded its fiscal year 2024 with robust performance. The company’s Q4 revenues rose by 27% to $84.7 million, and the total annual revenue growth was 28%, reaching $330 million. Twist Bioscience also exceeded its gross margin guidance for the quarter, achieving 45.1%, and noted an annual gross margin improvement to 42.6%.

    Baird has reaffirmed its Outperform rating on Twist Bioscience and increased the price target to $48.00. TD Cowen also reaffirmed its Buy rating for the company, emphasizing the company’s solid financial guidance for fiscal year 2025. Scotiabank (TSX:) raised its price target for the company to $54, maintaining a Sector Outperform rating.

    Twist Bioscience’s initial guidance for FY25 anticipates revenue growth between 17% to 20% year-over-year, largely driven by the Next (LON:) Generation Sequencing (NGS) and Synthetic Biology (SynBio) sectors. The company is also expected to improve its adjusted EBITDA by roughly $30 million year-over-year. These are among the recent developments shaping the future of Twist Bioscience.

    This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.





    Source link

    Share this:

    • Click to share on Facebook (Opens in new window) Facebook
    • Click to share on X (Opens in new window) X

    Like this:

    Like Loading...

    Related

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleMarjorie Taylor Greene Is Piling Into These 5 Unstoppable Artificial Intelligence (AI) Stocks as 2025 Starts
    Next Article New year, higher mortgage rates. What’s in latest Freddie Mac report?
    user
    • Website

    Related Posts

    3 mistakes to avoid when investing a SIPP

    June 8, 2025

    Here’s how to become a Stocks and Shares ISA millionaire by 2045!

    June 8, 2025

    Is Nvidia stock a massive bargain — or a massive value trap?

    June 8, 2025
    Add A Comment

    Leave a ReplyCancel reply

    © 2025 StockNews24. Designed by Sujon.

    Type above and press Enter to search. Press Esc to cancel.

    %d